The most frequently mutated genes in this cohort, present either in tumor, blood, or both, were TP53 (in 92% patients), NOTCH1 (in 84% patients), TERT (in 72% patients), CDKN2A (in 60% patients), MLL2 (in 56% patients) NOTCH2 (in 48% patients), BRCA2 (in 44% patients), and HNF1A (in 44% patients) (Figure 3). Here, CDKN2A is linked to neoplasm.